{"filing":{"accession_number":"0001178913-26-003339","cik":"0001801834","ticker":"PRFX","company_name":"PRF Technologies Ltd.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"zk2635607.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1801834/000117891326003339/zk2635607.htm"},"events":[{"id":13899,"run_id":12351,"accession_number":"0001178913-26-003339","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This exhibit is a press release announcing expanded preclinical study results for PRF-110, the company's lead product candidate, showing comparable analgesic efficacy to an approved benchmark (ZYNRELEF) with favorable pharmacokinetic properties. While the disclosure is clearly operational and product-development focused, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or litigation). As a clinical-stage pharmaceutical company's announcement of material preclinical progress on its lead candidate, this is a significant operational milestone that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","company_name":"PRF Technologies Ltd.","ticker":"PRFX","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":11174,"accession_number":"0001178913-26-003339","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing expanded preclinical study results for PRF-110, the company's lead product candidate, showing comparable analgesic efficacy to an approved benchmark (ZYNRELEF) with favorable pharmacokinetic properties. While the disclosure is clearly operational and product-development focused, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or litigation). As a clinical-stage pharmaceutical company's announcement of material preclinical progress on its lead candidate, this is a significant operational milestone that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:17:07.457913+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11174,"accession_number":"0001178913-26-003339","item_number":"EX-99.1","item_title":"exhibit_99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing expanded preclinical study results for PRF-110, the company's lead product candidate, showing comparable analgesic efficacy to an approved benchmark (ZYNRELEF) with favorable pharmacokinetic properties. While the disclosure is clearly operational and product-development focused, it does not fit the discrete event categories (no earnings release, M\u0026A, executive change, or litigation). As a clinical-stage pharmaceutical company's announcement of material preclinical progress on its lead candidate, this is a significant operational milestone that would affect a reasonable investor's assessment of the company's development trajectory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:17:07.457913+00:00","company_name":"PRF Technologies Ltd.","ticker":"PRFX","filing_date":"2026-06-25"}]}